NCT03202784

A Relative Bioavailability Study of Two Formulations of BCX7353

A Phase 1, Single-Dose, 3-Period Crossover Study to Evaluate the Relative Bioavailability of Two BCX7353 Capsule Formulations and to Evaluate the Effect of Food on BCX7353 Pharmacokinetics in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: BioCryst Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This is an open-label, randomized study to investigate the relative bioavailability of two formulations of BCX7353 and to determine if there is a food effect

Detailed description

In this study, 24 healthy subjects will be randomized to receive a single dose of two formulations of BCX7353 and one of the formulations administered with a high-fat meal. A 14-day washout period will separate each dose.

Conditions

• Hereditary Angioedema

Interventions

Type	Name	Description
DRUG	BCX7353	BCX7353

Timeline

• Start date: 2017-02-27
• Primary completion: 2017-08-01
• Completion: 2017-09-30
• First posted: 2017-06-29
• Last updated: 2020-01-27

Locations

1 site across 1 country: United Kingdom